MARC details
| 000 -LEADER |
|---|
| fixed length control field |
09426namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GICUC |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20251213122832.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
251212s2025 uaa|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.614 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
616.614 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.11.31.Ph.D.2025.We.D |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Wessam Moustafa Hussin, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Detection of incidence and outcomes of acute kidney injury in patients with covid-19, admitted to Cairo University Hospitals / |
| Statement of responsibility, etc. |
by Wessam Moustafa Hussin ; Supervisors Prof. Dr. Salwa Ibrahim, Prof. Dr. Dalia Roshd Ahmed Abdelrahman, Dr. Shady Ahmed Ramez. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
الكشف عن نسبه حدوث و نتائج الاصابه بالقصور الكلوي الحاد لدى مرضي كوفيد-19 المقبولين بمستشفيات جامعة القاهرة |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2025. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
160 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 134-160. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background <br/>The 2019 novel coronavirus disease (COVID-19) is a newly <br/>defined serious infectious disease caused by the SARS-CoV-2 virus. The <br/>epidemic started in Wuhan, China, in December of 2019 and quickly <br/>spread to over 200 countries. <br/>COVID-19 is characterized by acute respiratory disease, with 80% <br/>of patients presenting mild flu-like symptoms; however, 20% of patients <br/>may have a severe or critical clinical presentation, which likely causes <br/>multiple organ injuries (e.g., kidney, heart, blood, and nervous system). <br/>Among them, acute kidney injury (AKI) is a critical complication due to <br/>its high incidence and mortality rate. <br/>AKI is associated with high mortality rates in this setting, <br/>especially when renal replacement therapy is required. To date, there is <br/>no specific treatment for COVID-19 induced AKI. Further studies <br/>focusing on AKI in COVID-19 patients are urgently warranted in order to <br/>predict the risk of AKI, to identify the exact mechanisms of renal injury <br/>and to suggest targeted interventions. <br/>Patients and Methods <br/>This Cross-sectional analytic study comprised 661 Egyptian adult <br/>patients with confirmed COVID-19 infection admitted to Cairo <br/>University Hospitals. Incidence and severity of AKI was identified in <br/>patients using KDIGO clinical criteria. Outcomes of AKI were recorded <br/>including full recovery, partial recovery and the need for renal <br/>replacement therapy. The survival/mortality of the patients was also <br/>detected. Results <br/>The study included 661 patients, mean age was 47+/-14, showing <br/>male predominance 55.4%. Co-morbidities were found in 45.2% of the <br/>patients and it included Diabetes, hypertension, ischemic heart disease <br/>and chronic kidney disease. The patients included were 37.8% health <br/>care workers, 29.7% were smokers. Regarding severity of COVID-19 <br/>infection, our study included 33.7% mild infections, 53.7% moderate <br/>infection and 12.6% with severe infection. Regarding radiological <br/>findings 77.3% of the patients had positive findings while 22.7 patients <br/>had no findings. Regarding the outcomes of the COVID patients, 19.7% <br/>required ICU admission and needed assisted ventilator mechanisms with <br/>mortality incidence of 4.4%. The incidence of AKI in our study was <br/>25.4%, among those with AKI, 104 participants (61.9%) were in stage 1, <br/>45 participants (26.8%) were in stage 2, and 19 participants (11.3%) were <br/>in stage 3. Regarding the clinical manifestations of COVID patients with <br/>AKI, 56% of them presented with chest manifestation while the rest of <br/>them manifested with combined GIT, neurological, hematological <br/>manifestations. AKI patients were treated with symptomatic treatment in <br/>5.4%, steroids only in 40.5% of the cases and combination of steroids <br/>with tocilizumab in 54.2% <br/>Regarding the outcomes of COVID-19 patients with AKI, 64.3% <br/>returned to baseline creatinine levels, 35.7% did not. Renal replacement <br/>therapy in the form of intermittent hemodialysis was required for 6.5%. <br/>Our study found significant statistical correlations with p value <br/><0.001 between occurrence of AKI and older age, male sex, co-<br/>morbidities especially CKD, positive radiological findings, severity of <br/>COVID infection, thrombocytopenia, hypoalbuminemia, elevated ferritin <br/>levels, elevated D-dimer levels, leukocytosis, lymphopenia, elevated <br/>ALT, AST, Urea levels. <br/>Our study showed that full recovery of renal functions and less <br/>need for RRT was more in the group of patients who were treated with <br/>steroids only. There were also significant statistical correlations with p <br/>value <0.001 found between occurrence AKI and the need for ICU <br/>admission, assisted ventilation and mortality. <br/>RRT and severity of AKI was strongly correlated with mortality of <br/>AKI patients (p value <0.001). <br/>Conclusion <br/>Our study revealed that the incidence of AKI in COVID-19 <br/>patients admitted to Cairo University hospitals was 25.4%, with <br/>significant correlations identified between AKI and older age, male <br/>gender, comorbidities (diabetes, hypertension, IHD, CKD), and increased <br/>disease severity. The study also highlighted that AKI patients had worse <br/>outcomes, including higher rates of ICU admission, assisted ventilation, <br/>and mortality. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
المقدمة:<br/>تم اكتشاف فيروس كورونا 2 المرتبط بالمتلازمة التنفسية الحادة الشديدة لأول مرة في ديسمبر 2019، وهو المسبب لمرض فيروس كورونا. في البداية، كان يُعتقد أن تأثيره على الكلى محدود، لكن الأبحاث المتزايدة أكدت على ارتفاع معدل الإصابة بالأمراض الكلوية وشدتها، لا سيما القصور الكلوي الحاد لدى مرضى فيروس كورونا. وتُظهر الدراسات تفاوتًا كبيرًا في معدلات الإصابة بالقصور الكلوي الحاد، حيث تتراوح النسب بين 0.5% و42%. هذا التفاوت يعود جزئيًا إلى التحديات المنهجية والتحيزات المرتبطة بفترة الجائحة. كما تتفاقم هذه الفروقات بفعل اختلاف أنماط المرض وأساليب العلاج وتغيرات الفيروس عبر الزمن، مما يجعل التقارير المبكرة أقل دقة مقارنة بالدراسات الحديثة ذات الجودة العالية. ولا تزال الاختلافات الجغرافية والزمنية في ارتباط القصور الكلوي الحاد بفيروس كورونا غير مستكشفة بشكل كافٍ، رغم أهميتها الكبيرة.<br/>يحدث القصور الكلوي الحاد لدى مرضى فيروس كورونا نتيجة آليات مرتبطة مباشرة بالفيروس، مثل إصابة الخلايا عبر الإنزيم المحول للأنجيوتنسين 2، بالإضافة إلى عوامل غير محددة مثل التغيرات الديناميكية الدموية والأدوية السامة للكلى. يتم تشخيص القصور الكلوي الحاد وفقًا لمعايير مؤسسة تحسين النتائج العالمية لأمراض الكلى بناءً على الدمج بين البيانات الوبائية والسريرية والمخبرية. يؤدي القصور الكلوي الحاد إلى ارتفاع معدل الوفيات، خاصةً عندما تكون هناك حاجة للعلاج التعويضي الكلوي. حاليًا، لا توجد علاجات محددة للقصور الكلوي الحاد الناجم عن فيروس كورونا، كما أن تأثير العلاجات التجريبية لا يزال غير معروف. لذا، يُعد البحث المستقبلي أمرًا حاسمًا للتنبؤ بمخاطر الإصابة بالقصور الكلوي الحاد، وفهم آليات الإصابة الكلوية، وتطوير تدخلات علاجية موجهة لتحسين إدارة هذه الحالة لدى مرضى فيروس كورونا.<br/>الهدف من الدراسة:<br/>تهدف دراستنا بشكل أساسي إلى تحديد معدل حدوث ونتائج القصور الكلوي الحاد لدى مرضى فيروس كورونا في المجتمع المصري، نظرًا لندرة البيانات المتوفرة حاليًا في مصر. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Acute renal failure |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
قصور الكلى الحاد |
| 653 #1 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Acute kidney injury |
| -- |
COVID-19 |
| -- |
SARS-COV-2 |
| -- |
إصابة الكلى الحادة |
| -- |
كوفيد19 |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Salwa Ibrahim |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Dalia Roshd Ahmed Abdelrahman |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Shady Ahmed Ramez |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2025 |
| Supervisory body |
Salwa Ibrahim |
| -- |
Dalia Roshd Ahmed Abdelrahman |
| -- |
Shady Ahmed Ramez |
| Universities |
Cairo University |
| Faculties |
Faculty of Medicine |
| Department |
Department of Internal Medicine |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |